Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009:2009:826895.
doi: 10.1155/2009/826895. Epub 2010 Jan 24.

Oxandrolone Improves Height Velocity and BMI in Patients with Cystic Fibrosis

Todd Varness  1 , Erin E Seffrood, Ellen L Connor, Michael J Rock, David B Allen
Affiliations
Case Reports

Oxandrolone Improves Height Velocity and BMI in Patients with Cystic Fibrosis

Todd Varness et al. Int J Pediatr Endocrinol. 2009.

Abstract

Objective. To evaluate the effectiveness of oxandrolone in improving the nutritional status and linear growth of pediatric patients with cystic fibrosis (CF). Methods. Medical records of patients with CF treated with oxandrolone were reviewed for height z score, height velocity (HV), BMI z score, weight velocity (WV), Tanner stage, pulmonary function, liver enzyme levels, and any reported adverse events. Data were compared before (pre-Ox) and after (Ox) oxandrolone using a paired t-test. Results. 5 subjects (ages 8.5-14.5 years) were treated with oxandrolone 2.5 mg daily for 8-38 months. After 8-12 months of treatment, there was a statistically significant improvement in HV (pre-Ox = 5.3 +/- 1.4 cm/yr, Ox = 8.3 +/- 1.2 cm/yr, P < .01) and BMI z score (pre-Ox = -0.61 +/- 1.04, Ox = -0.30 +/- 0.86, P = .02). Both height z score (pre-Ox = -1.64 +/- 0.63, Ox = -1.30 +/- 0.49, P = .057) and WV (pre-Ox = 4.2 +/- 3.7 kg/yr, Ox = 6.8 +/- 1.0 kg/yr, P = .072) showed beneficial trends that did not reach statistical significance. No adverse events were reported. Conclusions. In this brief clinical report, oxandrolone improved the HV and BMI z score in patients with CF. Larger studies are needed to determine if oxandrolone is an effective, safe, and affordable option to stimulate appetite, improve weight gain, and promote linear growth in patients with CF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anthropometric data for subjects (n = 5) before and after initiation of oxandrolone.
See this image and copyright information in PMC

References

    1. Cystic Fibrosis Foundation. Annual Data Report to the Center Directors. Bethesda, Md, USA: Cystic Fibrosis Foundation; 2008. Patient Registry 2007.
    1. Sharma R, Florea VG, Bolger AP, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax. 2001;56(10):746–750. - PMC - PubMed
    1. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of Clinical Epidemiology. 1988;41(6):583–591. - PubMed
    1. Beker LT, Russek-Cohen E, Fink RJ. Stature as a prognostic factor in cystic fibrosis survival. Journal of the American Dietetic Association. 2001;101(4):438–442. - PubMed
    1. Zemel BS, Jawad AF, FitzSimmons S, Stallings VA. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. Journal of Pediatrics. 2000;137(3):374–380. - PubMed

Publication types